News
-
From May 5-9, RDD 2024 will welcome an international gathering of OINDP experts to the JW Marriott Starr Pass Resort and Spa in Tucson, AZ, which previously hosted RDD 2018. According to Richard Dalby of RDD… Read more . . .
-
AstraZeneca has announced that it will “expand the savings programs for its entire US inhaled respiratory portfolio,” capping costs at $35 per month for “eligible patients” as of June 1, 2024, while noting that “terms… Read more . . .
-
Kindeva Drug Delivery has named former West Pharmaceutical Services Senior Director, Business and Technical Operations, Jennifer Riter as VP of Analytical Services. Earlier this year, Kindeva announced the launch of its new analytical services business, which… Read more . . .
-
According to Optinose, the FDA has approved the company’s sNDA to extend use of Xhance fluticasone propionate nasal spray to include the treatment of chronic sinusitis without nasal polyps. Xhance was approved by the FDA for… Read more . . .
-
Device manufacturer Aptar Pharma announced that it will expand its production facility in Congers, NY, USA, including a significant increase in its capacity for manufacturing the Unidose (UDS) nasal delivery system. The expansion includes new cleanroom… Read more . . .
-
Inhalon Biopharma has announced the publication of two articles that present data from preclinical studies of the company’s inhaled “muco-trapping” technologies. The first, published in the journal Advanced Science, describes a study of nebulized delivery of… Read more . . .
-
AstraZeneca today announced the initiation of the Phase 3 ATHLOS and THARROS trials evaluating the effects of Breztri Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI on cardiopulmonary parameters and outcomes (including death) in COPD… Read more . . .
-
MannKind Corporation announced that it recently presented initial data from a meal challenge that was part of the Phase 4 INHALE-3 trial of Afrezza insulin DPI plus basal insulin injections versus standard of care in… Read more . . .
-
Vast Therapeutics has announced the appointments of former Aradigm Senior Medical Director Paul Bruinenberg as Chief Medical Officer and Chris Polage as Medical Director in preparation for clinical development of its ALX1 inhalation solution. Bruinenberg was most recently… Read more . . .
-
Boehringer Ingelheim said that “eligible patients” will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK